Last reviewed · How we verify
Emethibutin (ETHYLMETHYLTHIAMBUTENE)
Emethibutin (generic name: ETHYLMETHYLTHIAMBUTENE) is a drug. It is currently in Phase 2 development.
Emethibutin is a small molecule that works by interacting with specific biological pathways, but the exact mechanism is unknown.
Emethibutin, also known as Ethylmethylthiambutene, is a small molecule with unknown drug class and target. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a small molecule, it is likely to work by interacting with specific biological pathways, but the exact mechanism is unknown. Further research is needed to determine its potential therapeutic applications and safety profile. Due to the lack of information, it is difficult to provide a comprehensive summary of this compound.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ETHYLMETHYLTHIAMBUTENE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a complex orchestra, with many different instruments working together to create a harmonious whole. Emethibutin is like a new instrument that is being introduced into the orchestra, but we don't yet know how it will affect the overall sound or if it will even work in harmony with the other instruments. In pharmacological terms, Emethibutin is a small molecule that binds to specific receptors or enzymes, but the exact details of this interaction are still unknown.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Emethibutin CI brief — competitive landscape report
- Emethibutin updates RSS · CI watch RSS
Frequently asked questions about Emethibutin
What is Emethibutin?
How does Emethibutin work?
What is the generic name of Emethibutin?
What development phase is Emethibutin in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing